D.B. Root & Company LLC Sells 70 Shares of Becton, Dickinson and Company $BDX

D.B. Root & Company LLC lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.8% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,144 shares of the medical instruments supplier’s stock after selling 70 shares during the period. D.B. Root & Company LLC’s holdings in Becton, Dickinson and Company were worth $262,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC acquired a new position in Becton, Dickinson and Company during the first quarter valued at approximately $27,000. REAP Financial Group LLC boosted its position in Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 55 shares during the last quarter. Alpine Bank Wealth Management acquired a new position in Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC boosted its position in Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 99 shares during the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in Becton, Dickinson and Company during the first quarter valued at approximately $31,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Claire Fraser sold 863 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $192.30, for a total value of $165,954.90. Following the transaction, the director owned 23,143 shares in the company, valued at approximately $4,450,398.90. This trade represents a 3.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,214 shares of company stock worth $579,206 in the last 90 days. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Down 1.4%

BDX stock opened at $196.4380 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The stock has a market capitalization of $56.31 billion, a price-to-earnings ratio of 35.33, a PEG ratio of 1.49 and a beta of 0.20. The business’s fifty day moving average price is $180.10 and its two-hundred day moving average price is $195.89. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. The firm had revenue of $5.51 billion for the quarter, compared to analysts’ expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the business earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 74.82%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on BDX shares. Stifel Nicolaus reduced their price target on Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Bank of America lowered Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price objective on the stock. in a research note on Thursday, May 1st. The Goldman Sachs Group lowered Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 price objective on the stock. in a research note on Friday, May 2nd. Raymond James Financial lowered Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research note on Friday, May 2nd. Finally, Barclays dropped their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 3rd. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $211.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.